Pharma and Life Sciences CFO Jobs in Singapore: reconcile evidence before capital

One programme, four answers

The laboratory reports progress, the accounts record expense, the tax plan assumes qualification and cash is already committed

Each statement can be individually reasonable and collectively misleading. Scientific work may have reduced uncertainty without reaching a development threshold. Accounting may expense work that remains technically valuable. A Singapore tax claim may require location and activity evidence not present in the project system. Vendor contracts may commit future cash beyond the period shown as incurred cost.

The CFO should build four connected ledgers, not force one answer. Scientific owners define the question, uncertainty, investigation and result. Finance applies the relevant reporting policy. Tax owners test qualifying activity, location and expenditure. Treasury records paid, payable, committed, cancellable and contingent cash. The bridge explains differences and their decision consequence.

Strong career evidence shows one budget, tax benefit, financing or portfolio decision changed after reconciliation. It names personal authority and qualified challenge without disclosing proprietary research. A variance explanation is not enough when the underlying ledgers describe different work.

Decision-clock strip

Evidence, accounting, tax and liquidity mature on different dates

A board pack should show the date and confidence of each clock. Blending them into one percentage complete hides exactly what capital allocation needs to know.

Market boundary

Zero authorised Charters mean no CFO opening, financing window or SGD package

This page defines an evidence market. It makes no assertion about a named company's cash, programme value, tax claim, manufacturing investment, financing plan or hiring status.

R&D claim anatomy

The tax benefit is forecast before the project can explain which uncertainty it investigates in Singapore

IRAS distinguishes qualifying R&D from a departmental label and publishes different treatment for work conducted wholly in Singapore, outsourced Singapore activity and overseas work. For YAs 2024 to 2028, enhanced deductions can apply to specified qualifying Singapore staff costs and consumables under current conditions and limits.

The CFO should create a project record before year end: objective, scientific or technological uncertainty, systematic investigation, location, people, time, consumables, outsourced work, cost allocation, results and links to the ledger. Technical leaders own the science. Finance and tax owners preserve traceability and challenge classifications that follow budget convenience.

Do not count the deduction as certain cash merely because expenditure was approved. Model taxable position, utilisation, elections, review and timing with qualified advice. Candidate evidence should show a claim narrowed or excluded when project facts did not support it, along with the liquidity consequence.

Related-party conduct map

Singapore funds regional research while another entity owns the IP, decisions and residual return

Map who performs research, controls scientific and financial risk, owns or uses IP, supplies people and facilities, makes portfolio decisions, provides funding and receives product or licence returns. Add manufacturing, distribution, management services, guarantees, cost sharing and related-party loans. Agreements and invoices must match actual conduct.

IRAS publishes transfer-pricing rules and documentation guidance. The CFO should establish transaction-level owners, tested financial data, allocation logic, benchmarking where relevant, agreements, adjustments and contemporaneous documentation. A group policy cannot substitute for knowing how the Singapore entity behaved.

The board needs the option consequence too. A routine return may be arm's length for a limited function and leave Singapore funding capabilities it cannot control or retain. Tax compliance and enterprise strategy are distinct questions that should share the same fact map.

Minimum-tax readiness

A valuable incentive remains lawful and no longer produces the group effective rate assumed in the investment case

IRAS states that Singapore's MTT and DTT apply from financial years beginning on or after 1 January 2025 to in-scope multinational groups meeting the revenue and presence tests, including the stated EUR 750 million threshold measured in at least two of the preceding four years. Registration for relevant groups began in 2026.

The CFO should map constituent entities, ownership, accounting standards, elections, covered taxes, deferred tax, incentives, substance, data sources and filing responsibility. Do not decide scope from a Singapore entity's standalone revenue. Model cash and reporting consequences alongside the operational purpose of research, manufacturing or headquarters activity.

Rules and safe harbours continue to evolve. Qualified tax advisers determine application. Strong CFO evidence shows a location, incentive or investment decision re-performed after top-up tax changed the economics without treating tax rate as the only reason for real activity.

Clinical accrual evidence

Patient visits advance, vendor invoices lag and the close uses a percentage no operating owner recognises

Break clinical spend into evidence-bearing units: site activation, participant activity, visits, monitoring, laboratory work, data services, drug supply, pass-through cost and contract milestone. Each unit needs a source, cut-off, lag assumption, owner and later true-up. Use aggregate operational evidence rather than identifiable participant records where possible.

Separate purchase order, work performed, invoiced amount, paid cash, committed future spend and cancellable exposure. Review unusual reversals and vendors whose statements repeatedly disagree with site or clinical systems. The CFO should make uncertainty visible rather than force precision beyond the evidence.

A strong case shows a forecast, financing date or vendor term changed after accrual quality improved. It also acknowledges which estimate remained judgmental. Close speed is not control if the number depends on an undocumented conversation.

Validation before depreciation

The manufacturing asset is mechanically complete and cannot yet produce product the quality system can release

Build the capital model around use, not construction alone. Trace design, equipment, utilities, process transfer, engineering runs, qualification, validation, regulatory change, workforce, quality readiness, raw materials, yield, capacity and alternative supply. Record which commitments are cancellable and which create unavoidable cash.

Accounting classification and depreciation follow applicable standards and facts; investment value follows patient supply and portfolio need. The CFO should release tranches against evidence and preserve funds for investigation or remediation. A delayed validation date can move working capital, launch inventory, contract manufacturing and financing together.

Candidate proof should show when capital was paused, accelerated or redesigned because technical or quality evidence changed. The measure is option-aware stewardship, not spending to the approved envelope.

Collaboration value bridge

The partner announces a milestone and finance still has to determine rights, obligations, cash and recognition

Start with the executed contract and actual conduct. Map licences, territories, control, research and development obligations, decision committees, cost sharing, options, milestones, royalties, supply, termination, IP and data. Identify which event is achieved, approved, invoiced, collectible and constrained.

SFRS(I) standards issued through Singapore's accounting framework govern relevant reporting, but the answer depends on the contract and facts. Qualified accounting and tax owners determine recognition, measurement and disclosure. The CFO should prevent external storytelling from becoming the accounting conclusion.

Reconcile headline value to probability, timing, cost, tax, control transferred, future obligations and cash. Candidate evidence should show a transaction or board narrative changed after this bridge, not merely that the close booked it correctly.

Quality liquidity reserve

The defect is not yet probable enough for one accounting conclusion and is operationally urgent enough to require cash

Accounting recognition, disclosure, insurance recovery and operational funding are related but not identical. A quality or safety signal can require investigation, quarantine, alternate supply, remediation, recall preparation and communication before its final probability or amount is known.

Create scenarios with explicit triggers and authority. Protect qualified quality and medical decisions. Identify restricted cash, insurance conditions, supplier or partner recovery, covenant effect and the cost of preserving patients' supply. Update the board as evidence changes rather than letting a technical accounting label stand in for readiness.

Strong CFO evidence shows liquidity protected for an uncertain quality event and later released or expanded on facts. It excludes live defect details and privileged analysis from candidate material.

Finance evidence cabinet

Seven reconciliations distinguish capital authorship from technical accounting exposure

For each reconciliation record the starting assumption, personal authority, specialist advice, alternatives, decision, later evidence and remaining uncertainty. Remove confidential figures without removing the causal finance judgment.

Direct finance-leadership answers

Questions leaders ask before entering the Singapore pharma CFO market

Acceptance workbook

Rebuild one research programme from question to cash before taking responsibility for the forecast

Select a material programme. Trace its scientific question, Singapore and overseas activities, staff, vendors, consumables, accounting policy, tax treatment, transfer-pricing flows, accruals, commitments, milestones and next decision. Reconcile the project system, general ledger, tax workpapers, treasury view and board forecast.

Then map manufacturing and quality dependencies, product or licence rights, global decision authority, funding options and Pillar Two scope where relevant. Identify uncommitted financing, restricted balances, incentive assumptions, cost-sharing true-ups and quality scenarios that alter available liquidity.

Verify the close through evidence another reviewer can reperform. Review controls, systems, team capability, audit history, covenants, insurance, grants, key-person dependencies and work-pass needs. Label fact, estimate, advice and unknown.

The Charter should state which capital decisions the Singapore CFO can make when scientific, quality, global finance and commercial owners disagree. A runway number without those rights is not a finance mandate.